Group 1 - The core point of the article is the reintroduction of the fifth listing standard on the Sci-Tech Innovation Board, which supports unprofitable technology companies, marking a significant policy shift after nearly two years of suspension [2][4] - The new standard allows unprofitable companies with a projected market value of no less than 4 billion yuan and certain R&D achievements to go public, focusing on "technology valuation" as a key metric [4][11] - The reactivation of this standard is expected to provide significant financing opportunities for sectors like biomedicine and semiconductors, which had previously turned to overseas markets due to limited domestic options [7][11] Group 2 - The fifth listing standard's revival directly alters the financing landscape for unprofitable tech companies, with over 70 biomedicine firms having raised more than 1 billion yuan as of May 2025, many of which had stalled in their listing processes [7][11] - Companies utilizing the fifth standard have shown a significantly higher R&D investment intensity compared to the overall 12% level of the Sci-Tech Innovation Board, indicating a strong correlation between high R&D spending and market valuation [7][11] - The article emphasizes the need for companies to enhance their core technology development and establish a clear commercialization path to leverage the new policy effectively [13]